A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

A Pfizer drug recently awarded accelerated FDA approval in colorectal cancer now has additional data showing it met key goals in its pivotal study, results that could support an application ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...